IFNL1 and infection: Additional investigations in more relevant in vivo models of infection, such as mice or ferrets, will be necessary to further assess the efficacy of IFN λ1 + 6’SLN-CD formulation, with a more realistic administration protocol where both compounds are administered in post-treatment, and its genetic barrier to antiviral resistance.